Jade Biosciences to Participate in Upcoming Conferences
SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences:
- Guggenheim 3rd Annual Healthcare Innovation Conference
Fireside Chat: Tuesday, November 10, 2026 at 3:00 p.m. ET
Location: Boston, MA - Stifel Healthcare Conference
Fireside Chat: Wednesday, November 11, 2026 at 10:00 a.m. ET
Location: New York, NY - UBS Global Biopharma Conference
Fireside Chat: Monday, November 16, 2026 at 12:00 p.m. GMT
Location: London, UK - Jefferies Global Healthcare Conference
Fireside Chat: Tuesday, November 17, 2026 at 10:30 a.m. GMT
Location: London, UK
Members of the Jade management team will host one-on-one investor meetings during the conferences.
A live webcast of each of the fireside chats will be available on the Events page of the Jade Biosciences website, with an archived replay accessible for 90 days following the event.
About Jade Biosciences, Inc.
Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE301, an anti-IFN-β monoclonal antibody. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit JadeBiosciences.com and follow the Company on LinkedIn.
Jade Biosciences Contact
Zane Goodwin
IR@JadeBiosciences.com
Media@JadeBiosciences.com
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Growth Stocks to Buy While They’re Still Undervalued
3 of the Best Core Stocks to Own
The 10 Best Companies to Invest in Now
Your Year-End Financial Checklist: 5 Things to Tackle Before 2027
United States